US Patent

US11253528 — Stabilized modified release Vitamin D formulation and method of administering same

Formulation · Assigned to Eirgen Pharma Ltd · Expires 2034-03-14 · 8y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a stabilized formulation for controlled release of a vitamin D compound, specifically 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, with a cellulosic compound.

USPTO Abstract

A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.

Drugs covered by this patent

Patent Metadata

Patent number
US11253528
Jurisdiction
US
Classification
Formulation
Expires
2034-03-14
Drug substance claim
No
Drug product claim
Yes
Assignee
Eirgen Pharma Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.